BioMarin says VOXZOGO long-term trials improve arm span, maintain bone density in achondroplasia

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

BMRN

0.00
  • BioMarin outlined new long-term data for VOXZOGO in children with achondroplasia, scheduled for presentation at Pediatric Endocrine Society 2026 annual meeting in San Francisco.
  • Extension studies indicated sustained improvement in body proportionality measures, with bone health maintained over multi-year follow-up.
  • Separate research in hypochondroplasia is also set for presentation, with findings pointing to improved bone measures over 12 months.
  • Topline results from registration-enabling Phase 3 CANOPY-HCH-3 trial in hypochondroplasia expected in 1H 2026, with regulatory submissions planned for 2H 2026 if results are positive.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605021530PR_NEWS_USPR_____SF48576) on May 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.